Cargando…

Ocrelizumab Depletes CD20(+) T Cells in Multiple Sclerosis Patients

Ocrelizumab, a humanized monoclonal anti-CD20 antibody, has shown pronounced effects in reduction of disease activity in multiple sclerosis (MS) patients and has recently been approved for the treatment of patients with relapsing MS (RMS) and primary progressive MS (PPMS). CD20 is mainly expressed b...

Descripción completa

Detalles Bibliográficos
Autores principales: Gingele, Stefan, Jacobus, Thais Langer, Konen, Franz Felix, Hümmert, Martin W., Sühs, Kurt-Wolfram, Schwenkenbecher, Philipp, Ahlbrecht, Jonas, Möhn, Nora, Müschen, Lars H., Bönig, Lena, Alvermann, Sascha, Schmidt, Reinhold E., Stangel, Martin, Jacobs, Roland, Skripuletz, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6356421/
https://www.ncbi.nlm.nih.gov/pubmed/30597851
http://dx.doi.org/10.3390/cells8010012